申请人:Moffat David Festus Charles
公开号:US20100267774A1
公开(公告)日:2010-10-21
Compounds of formula (I) are inhibitors of p38 MAP kinase, and are therefore of utility in the treatment of, inter alia, inflammatory conditions including rheumatoid arthritis and COPD: formula (I) wherein: G is —N═ or —CH═; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members; R
6
is hydrogen or optionally substituted C
1
-C
3
alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula -A-(CH
2
)
z
—X
1
-L
1
-Y—NH—CHR
1
R
2
wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members; z, Y, L
1
, and X
1
are as defined in the specification; R
1
is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R
2
is the side chain of a natural or non-natural alpha amino acid.
式(I)的化合物是p38 MAP激酶的抑制剂,因此在治疗包括类风湿性关节炎和COPD等炎症疾病方面具有实用性:式(I)其中:G是—N═或—CH═; D是具有5-13个环成员的可选取代的二价单环或双环芳基或杂芳基基团; R6是氢或可选取代的C1-C3烷基; P代表氢,U代表式(IA)的基团; 或U代表氢,P代表式-A-(CH2)z-X1-L1-Y-NH-CHR1R2的基团,其中A代表具有5-13个环成员的可选取代的二价单环或双环碳环或杂环基团; z,Y,L1和X1如规范中所定义; R1是羧酸基(—COOH)或可由一个或多个细胞内酯酶酶水解为羧酸基的酯基; R2是天然或非天然α氨基酸的侧链。